Pancreatic neuroendocrine tumors: Nosography, management and treatment

详细信息    查看全文

• 作者：Michele Orditura^a ; ^{michele.orditura@unina2.it" class="auth_mail" title="E-mail the corresponding author} ; Angelica Petrillo^a ; ^{angelic.petrillo@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Jole Ventriglia^a ; ^{j.ventriglia@hotmail.it" class="auth_mail" title="E-mail the corresponding author} ; Anna Diana^a ; ^{annadiana88@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Maria Maddalena Laterza^a ; ^{marilena_laterza@yahoo.it" class="auth_mail" title="E-mail the corresponding author} ; Alessio Fabozzi^a ; ^{alessiofabozzi@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Beatrice Savastano^a ; ^{beasavastano@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Elisena Franzese^a ; ^{elifranzese@hotmail.it" class="auth_mail" title="E-mail the corresponding author} ; Giovanni Conzo^b ; ^{giovanni.conzo@unina2.it" class="auth_mail" title="E-mail the corresponding author} ; Luigi Santini^b ; ^{luigi.santini@unina2.it" class="auth_mail" title="E-mail the corresponding author} ; Fortunato Ciardiello^a ; ^{fortunato.ciardiello@unina2.it" class="auth_mail" title="E-mail the corresponding author} ; Ferdinando De Vita^a ; ^{ferdinando.devita@unina2.it" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Pancreatic neuroendocrine tumors (pNETs) ; Neuroendocrine carcinoma ; Pancreas ; Functional neuroendocrine tumors
• 刊名：International Journal of Surgery
• 出版年：2016
• 出版时间：April 2016
• 年：2016
• 卷：28
• 期：supp_S1
• 页码：S156-S162
• 全文大小：307 K

文摘

Pancreatic neuroendocrine tumors (pNETs) represent about 7% of all NETs, 8.7% of gastroenteropancreatic NETs (GEP-NETs) and 1–2% of all pancreatic neoplasms. In the last two decades, the increased diagnosis of pNETs has generated great interest and the development of different classifications, grading and staging systems. Recently, several trials were performed in order to improve the knowledge of biomarkers and imaging and to provide an early diagnosis, but their role is still under debate. Nowadays, surgery represents the only curative approach for pNETs. Approximately 90% of pNETs are silent and non-functional; therefore, most patients are diagnosed in late stage and present metastatic (60%) or locally unresectable advanced disease (21%) with a poor prognosis. Not many therapeutic options are available for pNETs, with different treatments for G1-G2 and G3 tumors, because these diseases are still rare and trials are made up of few series of patients. At present, medical treatments is controversial. On these bases, we believe that a multidisciplinary team composed of surgeons, oncologists, endocrinologists, radiation oncologists, radiologists, pathologists and medicals nuclear is required. This paper presents a review of present state-of-the-art in the field of pNETs.